MA52400B1 - Combined vaccine composition for multiple administration - Google Patents
Combined vaccine composition for multiple administrationInfo
- Publication number
- MA52400B1 MA52400B1 MA52400A MA52400A MA52400B1 MA 52400 B1 MA52400 B1 MA 52400B1 MA 52400 A MA52400 A MA 52400A MA 52400 A MA52400 A MA 52400A MA 52400 B1 MA52400 B1 MA 52400B1
- Authority
- MA
- Morocco
- Prior art keywords
- vaccine
- composition
- combination
- present
- combination vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 6
- 229940001442 combination vaccine Drugs 0.000 abstract 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 abstract 3
- 230000000845 anti-microbial effect Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 229960005323 phenoxyethanol Drugs 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 241000274177 Juniperus sabina Species 0.000 abstract 1
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 229940029583 inactivated polio vaccine Drugs 0.000 abstract 1
- 229940066827 pertussis vaccine Drugs 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A61K31/115—Formaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition immunogène à doses multiples pour un vaccin combiné multivalent, dans laquelle (i) le vaccin combiné multivalent contient un vaccin contre la coqueluche vaccin à cellules entières (wp) ou un vaccin contre la coqueluche acellulaire(ap), et un vaccin contre la polio inactivé sabin (sipv) ; et (ii) la composition contient du 2-phénoxyéthanol (2-pe) et du formaldéhyde (hcho) en tant que conservateurs ; et un procédé de préparation d’une composition immunogène à doses multiples pour un vaccin combiné multivalent. Il a été confirmé que la combinaison de 2-phénoxyéthanol et de formaldéhyde selon la présente invention est un excellent conservateur capable de maintenir une capacité antimicrobienne et qu’elle peut être efficacement utilisée pour produire une composition à doses multiples, maintenir la capacité antimicrobienne d’un vaccin combiné, ce de sorte que la composition de la présente invention puisse être efficacement utilisée dans l’industrie des vaccins combinés à doses multiples.The present invention relates to a multiple dose immunogenic composition for a multivalent combination vaccine, wherein (i) the multivalent combination vaccine contains a whole cell vaccine (wp) pertussis vaccine or an acellular pertussis (ap) vaccine, and sabin inactivated polio vaccine (ipsv); and (ii) the composition contains 2-phenoxyethanol (2-pe) and formaldehyde (hcho) as preservatives; and a method of preparing a multidose immunogenic composition for a multivalent combination vaccine. It has been confirmed that the combination of 2-phenoxyethanol and formaldehyde according to the present invention is an excellent preservative capable of maintaining antimicrobial capacity and can be effectively used to produce a multi-dose composition, maintain antimicrobial capacity of a combination vaccine, so that the composition of the present invention can be effectively used in the multiple dose combination vaccine industry.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150131157 | 2015-09-16 | ||
PCT/KR2016/010313 WO2017048038A1 (en) | 2015-09-16 | 2016-09-13 | Combination vaccine composition for multiple-dosage |
Publications (2)
Publication Number | Publication Date |
---|---|
MA52400A1 MA52400A1 (en) | 2022-06-30 |
MA52400B1 true MA52400B1 (en) | 2023-01-31 |
Family
ID=58289554
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42317A MA42317B2 (en) | 2015-09-16 | 2016-09-13 | Combination vaccine composition for multiple administration |
MA52400A MA52400B1 (en) | 2015-09-16 | 2016-09-13 | Combined vaccine composition for multiple administration |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42317A MA42317B2 (en) | 2015-09-16 | 2016-09-13 | Combination vaccine composition for multiple administration |
Country Status (7)
Country | Link |
---|---|
KR (1) | KR101864029B1 (en) |
BR (1) | BR112018005291A2 (en) |
EA (1) | EA037283B1 (en) |
MA (2) | MA42317B2 (en) |
PH (1) | PH12018500570A1 (en) |
TN (1) | TN2018000063A1 (en) |
WO (1) | WO2017048038A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018169303A1 (en) * | 2017-03-15 | 2018-09-20 | 주식회사 엘지화학 | Polyvalent streptococcus pneumoniae vaccine composition |
SG11202000224SA (en) * | 2017-07-18 | 2020-02-27 | Serum Inst Of India Pvt Ltd | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
JOP20190242A1 (en) * | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same |
WO2021176409A1 (en) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Preservative combination for vaccine composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920009729B1 (en) * | 1990-08-29 | 1992-10-22 | 주식회사 녹십자 | Mixed vaccine of d.p.t. and hepatitis b |
KR920009729A (en) * | 1990-11-26 | 1992-06-25 | 전금자 | Pottery manufacturing method that generates far infrared rays |
ES2118963T3 (en) * | 1992-05-23 | 1998-10-01 | Smithkline Beecham Biolog | COMBINED VACCINES, CONTAINING HEPATITIS B SURFACE ANTIGEN AND OTHER ANTIGENS. |
JP5416121B2 (en) * | 2007-09-12 | 2014-02-12 | ガルデルマ・リサーチ・アンド・デヴェロップメント | Use of excipients as preservatives and pharmaceutical compositions containing them |
PE20100365A1 (en) | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | NEW COMBINATION VACCINES WITH WHOLE CELL COUGH AND METHOD FOR THEIR PREPARATION |
BR112013022397A2 (en) * | 2011-03-02 | 2017-09-26 | Derek OHagan | vaccines combined with lower doses of antigen and / or adjuvant |
-
2016
- 2016-09-13 MA MA42317A patent/MA42317B2/en unknown
- 2016-09-13 EA EA201890502A patent/EA037283B1/en unknown
- 2016-09-13 WO PCT/KR2016/010313 patent/WO2017048038A1/en active Application Filing
- 2016-09-13 MA MA52400A patent/MA52400B1/en unknown
- 2016-09-13 KR KR1020160118261A patent/KR101864029B1/en active IP Right Grant
- 2016-09-13 TN TNP/2018/000063A patent/TN2018000063A1/en unknown
- 2016-09-13 BR BR112018005291A patent/BR112018005291A2/en active Search and Examination
-
2018
- 2018-03-15 PH PH12018500570A patent/PH12018500570A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112018005291A2 (en) | 2018-10-09 |
KR20170033254A (en) | 2017-03-24 |
KR101864029B1 (en) | 2018-06-01 |
PH12018500570A1 (en) | 2018-09-17 |
MA42317B2 (en) | 2021-11-30 |
EA201890502A1 (en) | 2018-08-31 |
EA037283B1 (en) | 2021-03-04 |
MA52400A1 (en) | 2022-06-30 |
TN2018000063A1 (en) | 2019-07-08 |
WO2017048038A1 (en) | 2017-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52400A1 (en) | Combined vaccine composition for multiple administration | |
CY1121418T1 (en) | HEPATITIS VIRUS INHIBITORS C | |
GT201500021A (en) | SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
CL2017002230A1 (en) | Combined treatment with a tlr7 agonist and inhibitor of vhb capsid assembly. | |
BR112018013387A2 (en) | recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit | |
UY36766A (en) | CYCLED SULFAMOILARILAMIDE DERIVATIVES AS VHB INHIBITORS, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EA201791516A1 (en) | METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS | |
EA202090098A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
BR112016008468A2 (en) | FORMULA COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND, USE OF A COMPOUND, AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF CANCER | |
AR101674A1 (en) | USE OF A TRICYCLIC COMPOUND CONTAINING NITROGEN | |
AR063057A1 (en) | IMMUNIZATION METHOD AGAINST THE 4 DENGUE SEROTYPES | |
CO6430434A2 (en) | NEW COMPOSITIONS OF VACCINES WITH ACCELULAR PERTUSSIS AND MANUFACTURING METHOD OF THE SAME | |
BR112019004560A2 (en) | combination treatment with tlr7 agonist and a hbv capsid formation inhibitor | |
AR108889A1 (en) | COMBINATIONS FOR CANCER TREATMENT | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
EA201590491A1 (en) | IMMUNOGENIC COMPOSITION | |
CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
ECSP16084317A (en) | PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE | |
IN2013MU00711A (en) | ||
AR108829A1 (en) | VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS | |
CO6430435A2 (en) | NEW VACCINES COMBINED WITH COMPLETE CELLS OF PERTUSSIS AND MANUFACTURING METHOD OF THE SAME | |
CY1124893T1 (en) | MAROPITANTIS MEDICINAL MIXTURE | |
AR112405A1 (en) | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES | |
PE20211648A1 (en) | COMPOSITION OF COMBINED VACCINE INCLUDING REDUCED DOSES OF INACTIVATED POLIO VIRUS AND METHOD OF PREPARING IT | |
MX2015010486A (en) | Chewable composition for oral administration and process for preparing thereof. |